Stay updated on Fenebrutinib vs Ocrelizumab in Primary Progressive MS Clinical Trial
Sign up to get notified when there's something new on the Fenebrutinib vs Ocrelizumab in Primary Progressive MS Clinical Trial page.

Latest updates to the Fenebrutinib vs Ocrelizumab in Primary Progressive MS Clinical Trial page
- Check2 days agoChange DetectedRemoval of the government funding/operating-status notice from the page does not affect the trial details or core information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check24 days agoChange DetectedCali, Colombia was added to the study locations and Santiago de Cali, Colombia was removed.SummaryDifference0.3%

- Check45 days agoChange DetectedUpdated the page to v3.2.0 with a government-operating status notice and related links; removed the previous v3.1.0 reference.SummaryDifference2%

- Check52 days agoChange DetectedUpdates add current dates, new locations/addresses, and an updated revision version; older locations and outdated addresses are removed. Overall, it reflects a refresh of core identifiers and contact details.SummaryDifference3%

- Check67 days agoChange DetectedLocalized the country name from Mexico to México in the address and updated the revision to v3.0.2; the 'Back to Top' link was removed.SummaryDifference1%

- Check74 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. Additionally, a 'Back to Top' feature has been added for improved navigation.SummaryDifference0.1%

Stay in the know with updates to Fenebrutinib vs Ocrelizumab in Primary Progressive MS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Fenebrutinib vs Ocrelizumab in Primary Progressive MS Clinical Trial page.